Clinical trials: Cancer Prostate
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council
Prostatic Neoplasms
Adjuvant Radiation Therapy vs. Watchful Waiting Following Radical Prostatectomy in High Risk Prostate Cancer
The purpose of this study is to determine whether adjuvant radiotherapy following radical prostatectomy in prostate cancer patients with positive margins or capsular penetration improves biochemical, overall and/or cancer…
- Trial name
- NCT02668718
- Testing
- Adjuvant radiotherapy
- Volunteers
- 250 people
- Sponsor
- Helsinki University Central Hospital
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Metastatic Castration Resistant Prostate Cancer (mCRPC)
The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA
- Trial name
- WB-LuPSMA (NCT05208229)
- Testing
- WB-MRI
- Where
- 2 sites in Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens.
- Trial name
- NCT00309894
- Testing
- sargramostim, ketoconazole, therapeutic hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Prostate Cancer
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.
- Trial name
- NCT00678054
- Testing
- GM-CSF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Anemia
Study of Aranesp to Treat Anemia in Prostate Cancer Patients.
The purpose of this study is to see if darbepoetin alfa is an effective treatment for anemia in prostate cancer patients and, if so, what dose is most effective.
- Trial name
- NCT00245895
- Testing
- Aranesp
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Prostatic Carcinoma
Expression of STEAP-1 and p40 in Prostatic Carcinoma and Its Mimickers
Prostatic carcinoma is the second most common cancer in men with high incidence of morbidity and mortality. It is a common health problem. Most cases occur at the age of 50 years, reaching its peak at 60-70 years of age.
- Trial name
- NCT05428319
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Prostatic Neoplasm
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment >90% of the patients would achieve and maintain castrate levels of serum…
- Trial name
- NCT00751790
- Testing
- triptorelin embonate (INN)
- Where
- South Africa
- Volunteers
- 120 people
- Sponsor
- Debiopharm International SA
Prostate Cancer
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
- Trial name
- fBTsRT (NCT04100174)
- Testing
- focal brachytherapy boost to SBRT
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Health-Related Quality Of Life
A Pilot Study of Remote Monitoring to Improve Health Related Quality of Life of Men Following Prostate Cancer Treatment.
The purpose of this study is to determine the feasibility of using digital technology and remote monitoring to track health-related measures in men following prostate cancer treatment.
- Trial name
- NCT03434535
- Testing
- Technology Intervention
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Johns Hopkins University
Prostate Cancer
Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer
RATIONALE: Nerve-sparing radical prostatectomy with nerve grafting followed by standard therapies for erectile dysfunction may be effective in helping patients with prostate cancer improve sexual satisfaction and quality of life.
- Trial name
- NCT00080808
- Testing
- Alprostadil (E1), Papaverine, Phentolamine mesylate
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy
This multicenter retrospective observational study aims to compare perioperative and postoperative outcomes between the da Vinci SP extraperitoneal approach (SP-EA) and the robotic multi-port transperitoneal approach (MP-TA) in…
- Trial name
- CoSMAP (NCT07666217)
- Where
- 8 sites in Japan
- Volunteers
- 625 people
- Sponsor
- Intuitive Surgical
Prostate Cancer, Benign Prostatic Hyperplasia
Application of DWI in Diagnosis of Prostate Cancer
This study compared the performance of different models of multiple b-value DWI in diagnosing prostate cancer.
- Trial name
- NCT04962269
- Testing
- MRI
- Volunteers
- 103 people
- Sponsor
- Peking University Third Hospital
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Prostate Cancer
Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour
Prostate cancer is the most common cancer diagnosed in men in Canada. Magnetic resonance imaging (MRI) may become a valuable tool to non-invasively identify prostate cancer and assess its biological aggressiveness, which in turn…
- Trial name
- MRI-PREDICT (NCT05024162)
- Testing
- MRT Accuracy, MRT Stability
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Nova Scotia Health Authority
Prostate Cancer
The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife
Giving a higher dose of radiation to the dominant tumour nodule within the prostate is hypothesized to improve tumour control. This trial will assess whether this technique, delivered in 5 treatments, can be delivered without…
- Trial name
- SPARC (NCT02145494)
- Testing
- Radiotherapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Castration-Resistant Prostate Cancer
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT01606982
- Testing
- MDV3100
- Sponsor
- Astellas Pharma Global Development, Inc.